How to Avoid Delays in Your Early Phase Oncology Trial?

Webinar: How to Avoid Delays in Your Early Phase Oncology Trial?

Many things can go array in your early phase oncology trials, from protocol development, taking care of a safety profile, getting the ethics committee / regulatory authority’s approval, managing vendors, and much more. They all cost precious time and increase the overall costs.

Despite the challenges, the number of oncology clinical trials increases year after year as more treatment options seek to reach the market. At the same time, these studies are becoming progressively more complex, bringing new challenges. So, often a simple question arises: how to avoid these delays in early phase oncology studies?

Planning your next oncology study?

Let’s talk how we can team up to overcome common challenges and ensure smooth processes.

What we will talk about?

How to avoid the most common delays in early phase oncology trials:

  • Protocol development
  • Safety profile
  • Seeking approvals by the Ethics Committee/Regulatory Authority
  • Safety Review Committees/Independent Monitoring Boards
  • IP manufacturing
  • Vendors and their management

Duration: 50 minutes.

Speakers:

  • Vladimir Mukovozchik, Head of Project Management
  • Artūras Pažėra, Senior Project Manager
Vladimir Mukovozchik

Vladimir Mukovozchik

Head of Project Management

Other content that might interest you:

No Results Found

The page you requested could not be found. Try refining your search, or use the navigation above to locate the post.

Running a clinical trial in the Baltic states

Running a clinical trial in the Baltic states

In the past five years, an average of 175 clinical trials are being initiated in the Baltic states each year. An average of 64,8% of the population in the Baltic states are in the age from 15 to 65 years old, the main target audience for clinical trials. Furthermore, a large pool of treatment-naïve subjects is available compared to other EU countries or the US. Patients with special therapeutic diseases are transferred to the main central hospitals.

read more
Remaining Vigilant and Compliant after Brexit: What’s next? (Latest Updates)

Remaining Vigilant and Compliant after Brexit: What’s next? (Latest Updates)

On 29th March 2017 UK submitted the notification of its intention to withdraw from the EU. This means that UK will become a ‘third country’ from 30th March’19. Even though leaving the EU with a deal remains the Government’s top priority, UK drug agency is publishing a series of guidance documents for industry and other stakeholders covering the proposed arrangements for the regulation of medicines, medical devices and clinical trials, if UK leaves EU with no deal.

read more
Tuberculosis Medicines Clinical Development in Eastern Europe and CIS

Tuberculosis Medicines Clinical Development in Eastern Europe and CIS

World Tuberculosis Day is commemorated every year on 24th March to raise awareness of tuberculosis, which is still causing death of nearly 1.5 million people each year, mostly in developing countries. It marks the day in 1882, when Dr. Robert Koch announced that he had discovered the cause of tuberculosis, the TB bacillus. In comparison to other infectious diseases caused by a single infectious agent, tuberculosis is the second biggest killer worldwide.

read more

Big Enough To Cover  All Your Needs. Small Enough To Care.

Discover the tailored solutions that Biomapas provides to accelerate your clinical trials and optimize your drug development process.

Clinical Research

Regulatory Affairs

Pharmacovigilance

Medical Information